Here are our current job openings. Please click on the job title for more information, and apply from that page if you are interested.
At Idera, our vision is to translate scientific breakthroughs into important new immunotherapies for the treatment of certain cancers and rare diseases. We have a culture where patients are at the center of all we do, with core Idera values that connect us to each other and our stakeholders and define who we are, what we stand for, and how we work.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera continues to invest in research and development, and is committed to working with investigators and partners who share the common goal of addressing the unmet needs of patients suffering from rare, life-threatening diseases. Our lead product candidate, IMO-2125, has demonstrated activity in a large array of pre-clinical models and is now demonstrating proof of concept in patients through both clinical and translational outcomes in PD-1 refractory melanoma patients. We are currently readying to initiate our global Ph3 study in early 2018. We are also looking forward to 2018 when we'll review topline data from our Ph2 drial of IMO-8400 in dermatomyositis, as well as initiate an IND for our first 3GA compound
To support these exciting and important programs, we are currently looking for an Associate Director/Director of Clinical Pharmacology who will support the development of novel oligonucleotide-based therapeutics from early phase to late phase and regulatory submission with a focus on immuno-oncology and rare disease therapeutic areas. He/she will serve as the clinical pharmacology lead on all Idera clinical study teams, contributing scientific insights to clinical study and program strategies as well as have tactical responsibilities for the execution of work by bioanalytical and other vendors, including review of qualifications, data, and reports.